The author argues oral GLP-1s like Novo Nordisk's sema and Eli Lilly's orfo will capture more than 25% of the obesity market by 2030, citing behavioral advantages over injections, and questions why analysts estimate such low penetration.
NVO — LONG The author argues oral GLP-1s like Novo Nordisk's sema will capture more than 25% of the total obesity market by 2030, contrary to analyst estimates. The author cites strong behavioral anchors such as fear of injection, pain, and the perception that injection therapy signals severe health problems, which should drive patients toward oral alternatives. The author acknowledges injectables may have better efficacy and lower side effects but believes oral benefits outweigh these factors.
Either way, I think that obesity pill(s) will have a great impact and they will definitely make more than 25% of total obesity market.
LLY — LONG The author argues oral GLP-1s like Eli Lilly's orfo will capture more than 25% of the total obesity market by 2030, contrary to analyst estimates. The author cites strong behavioral anchors such as fear of injection, pain, and the perception that injection therapy signals severe health problems, which should drive patients toward oral alternatives. The author acknowledges injectables may have better efficacy and lower side effects but believes oral benefits outweigh these factors.
Either way, I think that obesity pill(s) will have a great impact and they will definitely make more than 25% of total obesity market.
This Reddit post, published January 12, 2026, features u/MattieuOdd discussing NVO, LLY. 2 trade ideas extracted by AI with direction and confidence scoring.
Speakers: u/MattieuOdd · Tickers: NVO, LLY